FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stableThe FDA has rejected Sarepta Therapeutics’ new Duchenne muscular dystrophy (DMD) Vyondys 53 due to concerns about potential Share XFDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stablehttps://pharmaphorum.com/news/fda-says-no-to-sarepta-blocking-bid-to-expand-its-duchenne-stable/
ICER posts damning report on Sarepta’s Duchenne drug Exondys 51Controversy has dogged Sarepta’s Duchenne muscular dystrophy therapy Exondys 51 since its approval, and it’s not out of Share XICER posts damning report on Sarepta’s Duchenne drug Exondys 51https://pharmaphorum.com/news/icer-posts-damning-report-on-sareptas-duchenne-drug-exondys-51/
